What Is SANA/MVD1? The Experimental Molecule Targeting Energy Expenditure

Most modern obesity and metabolic treatments focus heavily on reducing appetite and food intake.

SANA, known as MVD1 during clinical development, is being investigated from a different direction.

Rather than primarily suppressing appetite, this experimental small molecule is designed to increase energy expenditure through creatine-dependent thermogenesis.

That makes SANA particularly interesting because it targets the other side of the energy-balance equation: not simply how much energy enters the body, but how much energy the body uses.

SANA is not a peptide.

It is an experimental small molecule derived from salicylate chemistry.

What Is SANA?

SANA stands for salicylic acid nitroalkene.

It is a modified derivative of salicylate, a chemical family that includes compounds related to aspirin.

Researchers developed SANA through drug-discovery work aimed at finding molecules capable of improving metabolic function.

During clinical development, SANA has been referred to as MVD1.

Published research in Nature Metabolism has investigated both its biological mechanism and its first use in human volunteers. (Nature⁠)

What Is Thermogenesis?

Thermogenesis is the process through which the body converts energy into heat.

Humans constantly produce heat as part of normal metabolism.

Certain tissues, particularly brown and beige fat, can increase this process under specific conditions.

Traditionally, much of the research into thermogenesis has focused on a protein called UCP1, which allows mitochondria to release energy as heat rather than storing it efficiently.

SANA appears to work differently.

Researchers found that its thermogenic effects were largely dependent on creatine metabolism rather than UCP1. (Nature⁠)

What Does Creatine Have to Do With Energy Expenditure?

Creatine is best known for its role in skeletal muscle.

Inside muscle cells, the creatine-phosphocreatine system helps rapidly recycle cellular energy.

But creatine metabolism also occurs in adipose tissue.

Scientists have identified what is sometimes described as a creatine-driven futile cycle.

In simplified terms, energy is repeatedly used to move creatine between different chemical states.

That process consumes energy and releases some of it as heat.

SANA appears to stimulate this pathway.

How Does SANA Work?

Preclinical research suggests that SANA increases mitochondrial respiration and stimulates creatine-dependent energy expenditure in fat tissue.

Researchers found increased thermogenesis in both brown and white adipose tissue.

Interestingly, the effect remained present under thermoneutral conditions.

That is important because many thermogenic effects observed in rodents occur partly because laboratory animals are maintained below their preferred environmental temperature.

SANA’s effects also appeared to operate independently of both UCP1 and AMPK signalling. (Nature⁠)

Why Is CKMT1 Important?

One of the key proteins involved in the mechanism appears to be mitochondrial creatine kinase, particularly CKMT1.

Creatine kinases help transfer high-energy phosphate groups between ATP and creatine.

Researchers found that disrupting creatine availability reduced SANA’s thermogenic effects.

Animals lacking the gene encoding mitochondrial creatine kinase also showed impaired responses to SANA.

These experiments strengthened the evidence that creatine metabolism plays a genuine role in the compound’s mechanism. (Nature⁠)

What Did the Animal Research Show?

In preclinical models of diet-induced obesity, researchers reported several metabolic effects after SANA administration.

These included:

• increased mitochondrial respiration
• increased energy expenditure
• increased thermogenesis
• reduced body weight
• reduced liver fat
• improvements in insulin resistance

These findings provided the basis for progressing the compound into early human research. (Nature⁠)

Has SANA Been Tested in Humans?

Yes.

This is one of the most important reasons SANA/MVD1 is worth following.

Researchers conducted a randomised, double-blind, placebo-controlled Phase 1A/B clinical trial.

The study consisted of two parts.

The first investigated single ascending doses in healthy lean volunteers.

The second investigated repeated doses over 15 days in volunteers with overweight or obesity.

Across both parts of the study, 41 participants were enrolled. (Nature⁠)

What Was the Main Purpose of the Trial?

The primary purpose was not to prove weight-loss effectiveness.

Phase 1 trials are mainly designed to investigate:

• safety
• tolerability
• pharmacokinetics
• how the body processes the compound

Researchers also collected exploratory information relating to:

• body weight
• glucose
• insulin
• metabolic markers

This distinction is important because small early-stage trials cannot provide the same level of evidence as larger Phase 2 or Phase 3 studies.

What Did the Human Study Find?

During the repeated-dose part of the trial, volunteers with overweight or obesity received MVD1 for 15 days.

Researchers reported preliminary changes involving:

• body weight
• fasting glucose
• insulin
• HOMA-IR, a marker related to insulin resistance

Participants receiving the highest repeated dose showed a statistically significant reduction in body weight during the 15-day study.

The researchers themselves stressed that these findings were exploratory because the trial was designed primarily to evaluate safety rather than clinical effectiveness. (Nature⁠)

Was SANA/MVD1 Well Tolerated?

The repeated-dose portion of the study showed a generally favourable short-term tolerability profile.

However, safety findings were not completely uneventful.

At the highest single dose of 800 mg, two participants experienced reversible kidney-related effects involving protein and glucose appearing in the urine.

These events were considered definitively related to the drug.

No definitively drug-related adverse events were reported during the multiple-dose portion, and no severe adverse events occurred during the study.

Researchers therefore concluded that further investigation was justified, while also making clear that larger and longer studies are needed. (Nature⁠)

How Is SANA Different From GLP-1 Medicines?

GLP-1-based medicines primarily influence pathways involving:

• appetite
• satiety
• gastric emptying
• glucose regulation

SANA appears to work through a very different mechanism.

Instead of mainly reducing energy intake, researchers are investigating whether SANA can increase energy expenditure through thermogenesis.

This makes the two approaches biologically distinct.

It also raises an interesting possibility for future metabolic research: combining therapies that influence both sides of energy balance.

That possibility remains experimental.

Is SANA Similar to ATX-304?

They are related in the sense that both are experimental metabolic compounds exploring energy expenditure rather than relying exclusively on appetite reduction.

Their mechanisms, however, are different.

ATX-304 is being investigated as an AMPK-network and mitochondrial activator.

SANA appears to increase energy expenditure through creatine-dependent thermogenesis and has been reported to operate independently of AMPK activation.

They therefore represent two separate experimental approaches to metabolic regulation.

Why Is Creatine-Driven Thermogenesis Important?

Scientists have known for years that the body can generate heat through mechanisms that do not rely entirely on UCP1.

Creatine cycling has emerged as one of these alternative pathways.

Recent research continues to investigate creatine-driven thermogenesis, including work published in 2026 showing additional molecular mechanisms controlling creatine-dependent heat production in adipose tissue. (Nature⁠)

This supports the broader scientific relevance of the pathway that SANA appears to target.

Does SANA Increase Metabolism?

The available evidence indicates that SANA increases energy expenditure and thermogenic activity in experimental models.

However, it would be premature to translate that into a simple claim that SANA reliably “boosts metabolism” in humans.

The human study was small and short.

Larger clinical trials are needed to determine whether the mechanism produces sustained increases in energy expenditure and meaningful long-term metabolic outcomes in people.

Is SANA a Fat-Burning Compound?

That description would oversimplify the research.

SANA is an investigational metabolic drug candidate.

Animal research indicates that it influences energy expenditure and adipose-tissue metabolism.

Early human research has produced encouraging signals involving body weight and glucose regulation.

But it has not yet been established as an approved treatment or proven long-term fat-loss therapy.

Why Is SANA/MVD1 Attracting Attention?

The main reason is its unusual mechanism.

Modern metabolic medicine has been transformed by appetite-based approaches.

SANA asks a different question:

Can energy expenditure itself be safely increased enough to improve metabolic health?

Creatine-dependent thermogenesis represents one potential way of doing that.

If future studies confirm the early findings, the pathway could become an important new area of metabolic drug development.

What Still Needs to Be Studied?

Several major questions remain.

Researchers need larger trials to determine:

• whether weight changes persist over longer periods
• how much energy expenditure actually increases in humans
• whether improvements in glucose regulation are reproducible
• optimal dosing
• longer-term kidney safety
• cardiovascular safety
• effects on lean body mass
• whether tolerance develops
• whether the compound works alongside other metabolic treatments

These questions cannot be answered from a 15-day Phase 1 study.

Is SANA a Peptide?

No.

SANA/MVD1 is a small-molecule drug candidate.

It belongs more appropriately in an Emerging Molecules or Metabolic Research category than within a conventional peptide section.

The Bottom Line

SANA, also known as MVD1 during clinical development, is an experimental small molecule designed to increase creatine-dependent thermogenesis and energy expenditure.

Published research has demonstrated a detailed biological mechanism in preclinical models and has also progressed into a first-in-human Phase 1A/B trial. (Nature⁠)

Early human findings involving body weight and glucose regulation are interesting, but the trial involved only 41 participants and was primarily designed to assess short-term safety and tolerability.

That means the evidence is promising rather than definitive.

What makes SANA particularly interesting is the underlying idea.

Rather than simply asking how appetite can be reduced, researchers are exploring whether the body’s own energy-expending machinery can be safely activated.

That makes creatine-dependent thermogenesis one of the more unusual emerging areas of metabolic research — and SANA/MVD1 one of the molecules worth watching.

This article is for research and educational purposes only and does not constitute medical advice or establish SANA/MVD1 as safe or effective for human use.